1. HOME
2. Research Insight
3. Market Leaders - 3D Bioprinting Market

The 3D bioprinting market is projected to reach USD 2.4 billion by 2029 from USD 1.3 billion in 2024, at a CAGR of 12.7% during the forecast period. Advancement in the 3D bioprinting technology, growing adoption of 3D bioprinting technology within the pharmaceutical & cosmetics sectors, rising public-private partnership & collaboration, increasing investments in research & development and the expenditure on medical devices.

The 3D bioprinting market is is highly fragmented. The prominent players operating in this market include BICO Group AB (Sweden), 3D Systems Inc. (US), Merck KGaA (Germany), Organovo Holdings Inc (US), Collplant Biotechnologies Ltd (Israel), regenHU (Switzerland), Aspect Biosystem (Canada), Advanced Solutions Life Sciences, llc (US), Cyfuse Biomedical K.K (Japan), Rokit Healthcare (South Korea), Hangzhou Genofei Biotechnology Co., Ltd. (China), Foldink (Armenia), Brinter (US) and among others. The key players of this market are mostly focusing on collaborations, acquisition, partnerships, agreement, expansion and advancements in 3D bioprinting technology.

To know about the assumptions considered for the study download the pdf brochure

BICO GROUP AB (Sweden)

BICO (Sweden) is a prominent player in the global 3D bioprinting market, boasting a diversified portfolio of products for 3D cell cultures for high-throughput drug screening and printing of human tissues and organs. The company has a strong geographic footprint with several subsidiaries and a global presence With a legacy of pioneering 3D bioprinting research and development, BICO boasts a diverse portfolio encompassing 3D bioprinters and bioinks for various research application including drug research and discovery. For instance, in May 2023, Cellink (Sweden), a BICO company, launched third-generation LUMEN X, the new standard for DLP bioprinting, to meet the needs of researchers and scientists who require high-resolution bioprinting capabilities

3D Systems, Inc. (US)

3D Systems, Inc. (US) held strong position in 3D bioprinting market in 2023. The company has strong product portfolio of 3D bioprinters, bioinks, and software, which assist in the layer-by-layer printing of 3D living tissues and emphasizes collaboration and partnerships with governments, non-profit organizations, and global health initiatives to improve bioprinting access and affordability, particularly in underserved regions. By investing in manufacturing capabilities and supply chain infrastructure, 3D sytems ensures the reliable production and distribution of 3D bioprinting products to meet global demand. For instance, in 2022, 3D Systems, Inc (US) established a new biotech firm, Systemic Bio, leveraging 3D Systems breakthrough and production-level bioprinting technology to create extremely precise vascularized organ models using biomaterials and human cells.

Merck KGAA (Germany)

Merck KGaA (Germany)) is also one of the key market player in the 3D bioprinting market. The majorly company focuses on both organic & inorganic growth strategies, i.e., product launches, expansion, agreements, collaborations and partnerships to strengthen its market dominance. For instance, in 2024, Merck established a distribution center in Brazil with an investment of USD 21.7 million to better serve its Life Science customers for faster deliveries in the region.

Related Reports:

3D Bioprinting Market by Component (3D bioprinters (Microextrusion, Inkjet, Laser), Bioinks, Software, Consumable), Material (Hydrogels, ECM), Application(Research (Regenerative Medicine, 3D cell Culture), Clinical (Skin, Bone)) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]